Prime Medicine (PRME) Short Interest Ratio & Short Volume

Short interest is the volume of Prime Medicine shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 19,250,000 shares of PRME short. 20.39% of Prime Medicine's shares are currently sold short. Learn More on Prime Medicine's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PRME shares currently have a short interest ratio of 5.0. Learn More on Prime Medicine's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.39% of Prime Medicine's floating shares are currently sold short.

Prime Medicine saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 19,250,000 shares, an increase of 4.8% from the previous total of 18,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Prime Medicine currently has issued a total of 134,574,000 shares. Some of Prime Medicine's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Prime Medicine currently has a public float of 94,420,000 shares.

20.39% of Prime Medicine's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Prime Medicine: IDEAYA Biosciences, Inc. (12.51%), Galapagos NV (3.27%), Arcutis Biotherapeutics, Inc. (15.67%), ANI Pharmaceuticals, Inc. (10.57%), Agios Pharmaceuticals, Inc. (8.75%), Disc Medicine, Inc. (9.15%), Belite Bio, Inc. Sponsored ADR (0.65%), Beam Therapeutics Inc. (26.10%), Recursion Pharmaceuticals, Inc. (37.26%), Harmony Biosciences Holdings, Inc. (8.70%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks.

Short selling PRME is an investing strategy that aims to generate trading profit from Prime Medicine as its price is falling. PRME shares are trading up $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Prime Medicine occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRME, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRME, twice per month. The most recent reporting period available is August, 31 2025.